Related Experiment Video
Updated: Jun 13, 2026
MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data
Published on: February 7, 2025
Oncogene-induced sensitization to chemotherapy-induced death requires induction as well as deregulation of E2F1
G Vignir Helgason1, Jim O'Prey, Kevin M Ryan
1Tumour Cell Death Laboratory, Beatson Institute for Cancer Research, Glasgow, United Kingdom.
Abstract:
The analysis of DNA tumor viruses has provided landmark insights into the molecular pathogenesis of cancer. A paradigm for this field has been the study of the adenoviral E1a protein, which has led to the identification of proteins such as p300, p400, and members of the retinoblastoma family. Through binding Rb family members, E1a causes deregulation of E2F proteins--an event common to most human cancers and a central pathway in which oncogenes, including E1a, sensitize cells to chemotherapy-induced programmed cell death. We report here, however, that E1a not only causes deregulation of E2F, but importantly that it also causes the posttranscriptional upregulation of E2F1 protein levels. This effect is distinct from the deregulation of E2F1, however, as mutants of E2F1 impaired in pRb binding are induced by E1a and E2F1 induction can also be observed in Rb-null cells. Analysis of E1a mutants selectively deficient in cellular protein binding revealed that induction of E2F1 is instead intrinsically linked to p400. Mutants unable to bind p400, despite being able to deregulate E2F1, do not increase E2F1 protein levels and they do not sensitize cells to apoptotic death. These mutants can, however, be complemented by either the knockdown of p400, resulting in the restoration of the ability to induce E2F1, or by the overexpression of E2F1, with both events reenabling sensitization to chemotherapy-induced death. Due to the frequent deregulation of E2F1 in human cancer, these studies reveal potentially important insights into E2F1-mediated chemotherapeutic responses that may aid the development of novel targeted therapies for malignant disease.
Insights
Adenoviral E1a protein upregulates E2F1, distinct from its known E2F deregulation. This E2F1 induction, linked to p400 binding, sensitizes cells to chemotherapy, offering new therapeutic targets for cancer.
Area of Science:
- Molecular biology
- Virology
- Cancer research
Background:
- DNA tumor viruses offer insights into cancer pathogenesis.
- Adenoviral E1a protein is a key regulator, interacting with proteins like p300, p400, and retinoblastoma (Rb) family members.
- E1a-mediated deregulation of E2F proteins is common in human cancers and influences chemotherapy sensitivity.
Purpose of the Study:
- To investigate the role of adenoviral E1a protein in regulating E2F1 protein levels.
- To determine the mechanism by which E1a influences E2F1 and its impact on chemotherapy-induced apoptosis.
- To explore the potential therapeutic implications of E1a-E2F1 interactions in cancer treatment.
Main Methods:
- Analysis of adenoviral E1a mutants with varying cellular protein binding capabilities.
- Assessment of E2F1 protein levels and E2F deregulation in cells expressing E1a mutants.
- Investigation of the role of p400 and Rb family proteins in E1a-mediated E2F1 induction.
- Evaluation of chemotherapy-induced apoptosis in response to E1a activity and E2F1 levels.
Main Results:
- E1a causes posttranscriptional upregulation of E2F1 protein, independent of Rb binding.
- E2F1 induction by E1a is intrinsically linked to p400 binding.
- E1a mutants deficient in p400 binding do not induce E2F1 or sensitize cells to apoptosis.
- Restoration of E2F1 induction via p400 knockdown or E2F1 overexpression re-enables chemotherapy sensitization.
Conclusions:
- Adenoviral E1a protein's ability to induce E2F1 protein levels is mediated by p400, not Rb.
- E2F1 upregulation by E1a is crucial for sensitizing cancer cells to chemotherapy-induced death.
- These findings highlight E2F1's role in chemotherapeutic responses and suggest novel targeted therapy strategies for cancer.
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:46Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:06Induced Pluripotent Stem Cells
Somatic cells are...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...